M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy.

In the teplizumab group, M120 decreased over 6 months (11.6 [1.5] to 11.3 [1.5]; P = 0.036) to reveal a highly significant difference between the teplizumab and placebo groups ( P < 0.001).

also in 132,142 other papers